ArticleESMO gastrointestinal oncology2026
Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with metastatic colorectal cancer (mCRC) who have progressed on fluoropyrimidines, oxaliplatin, irinotecan, anti-angiogenic agents, and anti-epidermal growth factor receptor (EGFR) therapies have limited treatment options and poor prognosis, with a median overall survival (mOS) of ∼6 months on single-agent regorafenib or trifluridine/tipiracil. The addition of bevacizumab to trifluridine/tipiracil improved mOS to 10.8 months, and fruquintinib, a selective vascular endothelial growth factor receptor (VEGFR) 1-3 inhibitor, improved mOS to 7.4 months versus 4.8 months with placebo in refractory mCRC. However, combinations of tyrosine kinase inhibitors and immune checkpoint inhibitors have shown benefit primarily in patients without liver metastases in microsatellite stable mCRC, likely due to liver-associated immunosuppression. The QUINTIS trial evaluates whether fruquintinib plus tislelizumab can improve outcomes to the standard of care with trifluridine/tipiracil and bevacizumab in third-line and beyond mCRC. Methods/design: QUINTIS is a prospective, randomized, open-label, multicenter, phase II trial enrolling patients with advanced or metastatic colorectal adenocarcinoma without active liver metastases who have been previously treated with fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, and, if indicated, an EGFR inhibitor. Participants are randomly assigned 1 : 1 to one of the following treatment arms: arm A (experimental): fruquintinib 5 mg orally once daily on days 1-21 of a 4-week cycle (q4w) plus tislelizumab 400 mg intravenously on day 1 every 6 weeks (q6w); or arm B (control): trifluridine/tipiracil 35 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.